PROBLEMS OF ANTIBIOTIC THERAPY IN KOVID-ASSOCIATED HOSPITAL PNEUMONIA

Introduction. The advent of the COVID-19 pandemic has posed challenges to healthcare professionals. The most common manifestation of a new variant of coronavirus disease is pneumonia, and therefore, the doctor is faced with the question of the diagnostic value of certain indicators, as well as - the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Сучасні медичні технологіЈі 2022-06 (2), p.30-35
Hauptverfasser: Savchenko, O. A., Podsevahyna, S. L., Tkachenko, A. V., Myrnyi, D. P., Katsiuba, Y. V., Myrna, A. I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction. The advent of the COVID-19 pandemic has posed challenges to healthcare professionals. The most common manifestation of a new variant of coronavirus disease is pneumonia, and therefore, the doctor is faced with the question of the diagnostic value of certain indicators, as well as - the feasibility of prescribing antibacterial therapy. The purpose of the study was to assess the importance of clinical, imaging, laboratory methods for diagnosing the condition of patients with covid-associated pneumonia, to determine the nuances of the possible appointment of antibacterial therapy. Current text. The main problem in the diagnosis of covid-associated pneumonia is the need to differentiate between viral lung disease and the development of secondary bacterial pneumonia. Viral pneumonia can be of varying severity, but does not require antibacterial therapy. At the same time, the accession of bacterial flora on the background of viral lung disease, requires the immediate appointment of antibacterial drugs. It should be noted that the available data to date indicate that the accession of bacterial infection to viral lung disease is confirmed in no more than 8-10% of patients, ie most patients with coronavirus do not require antibiotics [1,2, 3]. At the same time, worldwide, antibiotics associated with pneumonia-associated pneumonia are unreasonably common and, according to some studies, the proportion of patients receiving antibacterial therapy ranges from 27% to 84% [1,4,5]. Conclusions. The problem of managing patients with covid-associated pneumonia is due to the fact that, to date, there is no specific criterion that would clearly distinguish viral lung disease from viral-bacterial. Traditionally, data from clinical, laboratory and instrumental research methods are used for the differential diagnosis of viral and bacterial pneumonia. A common approach to antibiotic treatment in many cases is not only unjustified, but also leads to a massive increase in antibiotic resistance with subsequent complications. In each case, the decision must be made individually, taking into account the full range of diagnostic and clinical aspects.
ISSN:2072-9367
DOI:10.34287/MMT.2(53).2022.6